J
Jacobio Pharmaceuticals
Clinical-stage oncology biotech developing small-molecule drugs for undruggable cancer targets, including KRAS and SHP2 inhibitors
About Jacobio Pharmaceuticals
Jacobio Pharmaceuticals (HKEX: 1167) is a clinical-stage biopharmaceutical company founded in Beijing in 2015 that discovers and develops small-molecule oncology drugs aimed at historically difficult-to-drug cancer targets, including KRAS, SHP2, P53, MYC and RB pathway proteins. The company operates R&D centres in Beijing and Shanghai, China and Boston, US, and develops its candidates through its Induced Allosteric Drug Discovery Platform (IADDP) together with a next-generation antibody-drug conjugate programme (iADC) that uses targeted drugs, immune stimulators and oligonucleotides as payloads instead of toxins.
The lead programme, glecirasib (JAB-21822), a KRAS G12C inhibitor, was approved by China's NMPA in May 2025 for previously treated non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation; China rights for glecirasib and the SHP2 inhibitor sitneprotafib (JAB-3312) are licensed to Shanghai Allist Pharmaceuticals. A Phase III registration trial evaluating sitneprotafib plus glecirasib as first-line treatment for KRAS G12C-mutant NSCLC has been ongoing in China since August 2024. In December 2025 Jacobio entered a global exclusive licence agreement with AstraZeneca for its pan-KRAS inhibitor JAB-23E73 (US$100 million upfront, up to US$1.915 billion in milestones plus tiered royalties), with the two companies jointly developing and commercialising the candidate in China.
The company generates revenue primarily through out-licensing agreements and strategic collaborations with pharmaceutical partners. Its pipeline also includes Aurora A, BET, P53 Y220C activator, CD73 antibody and STING-based iADC programmes in clinical or preclinical development, and clinical trials run at over 180 sites in China, more than 30 in the US and over 10 in Europe.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2015
- Headquarters
- Dongcheng District, China
- Listing
- IPO 2020
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 23.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 1 company, latest Aug 2021
- Capital deployed
- $53M
- Preferred round
- SERIES A
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Sep 2025 | $12M | — | Undisclosed | ↗ |
| IPOOther financing | Dec 2020 | $174M | $174M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $7.4M | 0% | −$20M | -275.2% |
| 2025 | $7.4M | -65.6% | −$20M | -275.2% |
| 2024 | $21M | +145.1% | −$17M | -80% |
| 2023 | $8.7M | -33.7% | −$43M | -496.5% |
| 2022 | $13M | -37.3% | −$49M | -368.4% |
| 2021 | $21M | -68.6% | −$41M | -195.9% |
| 2020 | $67M | — | $26M | 39% |
Growth signals
Latest recorded traffic for Jacobio Pharmaceuticals is 170 monthly website visits, down 10.5% over the last three months. Jacobio Pharmaceuticals's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jacobio Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jacobio Pharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.